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Introduction
Gabarapl1/gec1 (gabarap-like 1 protein/glandular epithelial cell 
1) is an estrogen-regulated gene that belongs to the gabarap 
(GABA
A
 receptor-associated protein) family of genes. It has been 
demonstrated that GABARAPL1 acts in receptor and vesicle 
transport thanks to its interaction with tubulin and the GABA
A
 
and kappa-opioid receptors.1,2 GABARAPL1 also plays a role, 
like GABARAP, GATE-16 and LC3, in the process of auto-
phagy and can be now considered as an autophagic marker as 
well.3 The exact role of GABARAPL1 in intracellular transport 
and autophagy, however, is still unanswered, and will require fur-
ther studies to address the remaining uncertainties. As with any 
experiment, the proper tools are critical to its success. As such, 
one essential technical question will have to be answered before 
the in vivo role of GABARAPL1, and similarly, the role of its 
closest homolog, GABARAP, can be elucidated: the question of 
the specificity of the currently available polyclonal anti-GAB-
ARAPL1 and anti-GABARAP antibodies. Indeed, we know that 
these two proteins share 86% identity at the amino-acid level 
(Fig. 1) and that the crystal structures of these proteins present 
identical tri-dimensional structures, similar to that of the ubiq-
uitin protein.4-6 These shared features make it very difficult to 
Atg8 is a yeast protein involved in the autophagic process and in particular in the elongation of autophagosomes. 
in mammals, several orthologs have been identified and are classed into two subfamilies: the Lc3 subfamily and the 
GABArAp subfamily, referred to simply as the Lc3 or GABArAp families. GABArApL1 (GABArAp-like protein 1), one of 
the proteins belonging to the GABArAp (GABAA receptor-associated protein) family, is highly expressed in the central 
nervous system and implicated in processes such as receptor and vesicle transport as well as autophagy. the proteins 
that make up the GABArAp family demonstrate conservation of their amino acid sequences and protein structures. in 
humans, GABArApL1 shares 86% identity with GABArAp and 61% with GABArApL2 (GAte-16). the identification of the 
individual proteins is thus very limited when working in vivo due to a lack of unique peptide sequences from which 
specific antibodies can be developed. Actually, and to our knowledge, there are no available antibodies on the market 
that are entirely specific to GABArApL1 and the same may be true of the anti-GABArAp antibodies. in this study, we sought 
to examine the specificity of three antibodies targeted against different peptide sequences within GABArApL1: cHeM-
ceNt (an antibody raised against a short peptide sequence within the center of the protein), ptG-Nter (an antibody 
raised against the N-terminus of the protein) and ptG-fL (an antibody raised against the full-length protein). the results 
described in this article demonstrate the importance of testing antibody specificity under the conditions for which it will 
be used experimentally, a caution that should be taken when studying the expression of the GABArAp family proteins.
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produce a specific antibody directed against only one of these two 
proteins. Moreover, in humans, GABARAPL1 shows 61% iden-
tity with GATE-16,7 54% with yeast Atg8 (autophagy-related 
protein),8 and 28.8% with MAP-LC3 (light chain 3 of microtu-
bule associated protein).9-11
GABARAPL1 was first discovered in 1993 and described as 
part of the GABARAP family in 2001.12 When performing a far 
from exhaustive search on PubMed, we counted about 31 pub-
lications citing this protein (using three different names: GEC1, 
GABARAPL1 or GABARAP-L1). Within these 31 publications, 
only nine presented antibody-detection of the GABARAPL1 
protein. The majority of these publications examine the expres-
sion of gabarapl1 at the mRNA level.
Since the discovery of GABARAPL1 in our laboratory, we 
have endeavored to identify reliable tools to study this protein 
and have developed an appreciation for the technical problems 
linked to these tools. The main problem is that GABARAP and 
GABARAPL1 are so closely related (86% identity, Fig. 1) that 
their in vivo immunodistinction becomes very improbable. This 
problem can be easily circumvented when working with immu-
noblotting analysis. Although their calculated molecular weights 
are identical (14 kDa), GABARAPL1 displays a slower migration 
rate than GABARAP, allowing one to separate the two proteins 
© 2011 Landes Bioscience.
Do not distribute.
www.landesbioscience.com Autophagy 1303
 BAsic Brief report BAsic Brief report
antibody directed against either GABARAPL1 or GABARAP is 
currently available.
To investigate the specificity of these antibodies against dena-
tured GABARAPL1 and GABARAP, we performed protein gel 
blot analysis with HEK293 WT and FLAG-GABARAPL1-6HIS 
stably expressing HEK293 cell lysates (Fig. 2A). Antibodies 
directed against the FLAG peptide and Actin were used as inter-
nal controls of FLAG-GABARAPL1-6HIS protein expression 
and total amounts of loaded proteins, respectively. While these 
cell lines both express an easily detectable amount of GABARAP, 
endogenous GABARAPL1 expression is very weak, necessitat-
ing the use of the FLAG-GABARAPL1-6HIS stably transfected 
HEK293 cell line in order to more easily visualize GABARAPL1 
in these lysates. All three antibodies tested displayed a relatively 
strong signal at approximately 18 kDa in size (Fig. 2A, lanes 
1, 3 and 5), corresponding to FLAG-GABARAPL1-6HIS in 
the stably expressing cell line. In addition, the antibody raised 
against a central peptide of the GABARAPL1 protein (CHEM-
CENT) revealed a second very intense band at approximately 15 
kDa in size (Fig. 2A, lanes 5 and 6), corresponding to endog-
enous GABARAP. Surprisingly, despite the presence of a stably 
expressed recombinant GABARAPL1 protein this antibody pro-
duced a prominent band for the endogenous GABARAP protein, 
suggesting that this antibody equally recognizes the two proteins.
Given that protein-antibody interactions can vary depending 
on the amount of protein expressed, we chose to confirm these 
results with transient transfections of either GFP-GABARAPL1 
or GFP-GABARAP prior to protein gel blot analysis of the protein 
lysates (Fig. 2B). An antibody directed against GFP was used as 
an internal control of the fusion proteins’ expression in the cells. In 
accordance with the previous results, the antibody raised against 
the central peptide (CHEM-CENT) displayed a 40 kDa band for 
both GFP-GABARAPL1 and GFP-GABARAP (Fig. 2B, lanes 5 
and 6). In contrast, when GABARAPL1 and GABARAP are over-
expressed, only one antibody of the two previously identified to be 
specific remained so. The antibody produced with the N-terminal 
peptide (PTG-NTER) detected both the GFP-GABARAPL1 and 
the GFP-GABARAP (Fig. 2B, lanes 1 and 2), suggesting that 
this antibody is not specific when both proteins are overexpressed. 
The antibody directed against the full-length peptide (PTG-FL), 
however, continued to identify only the GABARAPL1 protein 
(Fig. 2B, lane 3), producing only one signal corresponding to the 
with a higher percentage of acrylamide in the gel and a longer 
migration time.3,13 Immunohistological analysis of the endog-
enous proteins, however, does not provide an easy alternative 
to the necessity of specific antibodies. Indeed, many researchers 
have encountered this problem of cross-reactivity with both their 
‘homemade’ and commercially bought antisera and purified anti-
bodies raised against either GABARAPL1 or GABARAP.1,2,14 To 
our knowledge, there are no available antibodies that can dif-
ferentiate between these two proteins, explaining why so many 
laboratories have chosen to use the less problematic mRNA-based 
techniques to overcome this problem and study the expression of 
these genes in vivo. While these studies have allowed for a bet-
ter characterization and understanding of gabarapl1 gene expres-
sion and regulation, they do not explore GABARAPL1 protein 
expression and regulation.
In the past, GABARAPL1 has been the subject of only a 
handful of studies, while most laboratories focused their efforts 
on other members of the GABARAP and LC3 families such as 
GABARAP, GATE-16 and LC3 as well as the yeast homolog, 
Atg8. Our recent paper establishing GABARAPL1 as a new 
autophagic marker, however, may trigger a new wave of research 
on this protein. The interest in GABARAPL1 functionality, 
in particular in the brain where it is the most highly expressed 
gene of the family,15 is likely to grow in the future. Before that 
time comes, we wish to present several pieces of data explaining 
our concerns about the detection of the GABARAPL1 protein 
in vitro and in vivo in regards to its high homology with the 
GABARAP protein.
Results
In this work, we studied three anti-GABARAPL1 antibodies 
among those that are commercially available: one directed against 
the full-length GABARAPL1 protein (PTG-FL, 11010-1-AP, 
Proteintech), a second raised against a short peptide sequence at 
the N-terminal of the protein (PTG-NTER, amino acids 4–18, 
QYK EDH PFE YRK KEG, 18721-1-AP, Proteintech) and a 
third raised against a longer peptide sequence in the center of the 
protein (CHEM-CENT, amino acids 35–84, KAP KAR VPD 
LDK RKY LVP SDL TVG QFY FLI RKR IHL RPE DAL FFF 
VNN TI, AB15278, Chemicon) (Fig. 1). All antibodies used are 
rabbit polyclonal antibodies. It is noteworthy that no monoclonal 
Figure 1. Alignment of peptide sequences used to produce anti-GABArApL1 antibodies with GABArApL1 and GABArAp. the human amino-acid 
sequences (obtained from NcBi or GeneBank databases) of GABArApL1 (Np_113600) and GABArAp (cAG47031) proteins were aligned using the NcBi 
protein BLAst tool. the amino acid sequences of the peptides used to produce anti-GABArApL1 are highlighted in blue (ptG-Nter, proteintech, 
18721-1-Ap) and in green (cHeM-ceNt, chemicon, AB15278). Variation between the GABArAp and GABArApL1 proteins are shown in red.
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inhibited by incubation with recombinant GABARAP, suggest-
ing that, under the conditions used, these antibodies also recog-
nize this homolog protein.
Discussion
In this work, we studied the characteristics of three different 
anti-GABARAPL1 antibodies in protein gel blot and immuno-
histochemical analysis. With the exception of the anti-ATG8L 
antibody from Protein Tech Group (PTG-FL), these antibodies 
are described to be specific to GABARAPL1, implying that they 
do not recognize the closest homolog, GABARAP.
Using HEK293 cell lysates, we demonstrated that the anti-
bodies tested displayed differing affinities for the denatured 
forms of GABARAPL1 and GABARAP. Of the antibodies that 
GFP-GABARAPL1. These results suggest that this anti-
body remains specific to GABARAPL1 whatever the lev-
els of overexpressed proteins.
In order to examine the ability of these antibodies to 
discern between native GABARAPL1 and GABARAP, 
we performed liquid phase inhibition experiments fol-
lowed by immunohistochemical analysis. Given the 
known high expression of gabarapl1 mRNA in the 
mouse brain and the fact that GABARAPL1 inter-
venes in the transport of neuronal receptors, we chose 
to conduct these studies on mouse cerebral sections. 
The respective antibodies were incubated alone or with 
either full-length recombinant FLAG-GABARAPL1-
6HIS or FLAG-GABARAP-6HIS for two hours prior 
to incubation on mouse coronal brain sections overnight 
followed by classical immunofluorescent detection meth-
ods. Staining intensity was then analyzed throughout the 
slice and representative images of three separate experi-
ments were taken in the cortex. In the presence of the 
individual antibodies alone, the visible staining pattern 
varied from one antibody to another. The antibody raised 
against the full-length protein (PTG-FL) displayed the 
highest background and marked the cytoplasm of cells 
with a more intense vesicular staining within the cyto-
plasm as well as a fainter fiber-like staining pattern (Fig. 
3A). The antibody raised against the N-terminal of the 
GABARAPL1 protein (PTG-NTER) displayed a similar 
staining pattern although the background staining was 
drastically reduced and fibril-like staining increased (Fig. 
3D). Finally, the third antibody, raised against the cen-
tral part of the GABARAPL1 protein (CHEM-CENT), 
displayed a much weaker signal in the cytoplasm of 
cells and a more prominent vesicular pattern through-
out the section (Fig. 3G). After incubation with the 
FLAG-GABARAPL1-6HIS protein, all three antibodies 
were attenuated and little to no positive staining could 
be found in the corresponding sections, indicating that 
all three antibodies clearly recognize the GABARAPL1 
protein in its native form (Fig. 3B, E and H). The 
results obtained from the incubation with the FLAG-
GABARAP-6HIS protein, however, differed depending 
on the antibody in question. Incubation of the PTG-FL antibody 
with recombinant GABARAP did not appear to affect staining 
intensity at all (Fig. 3C), demonstrating that under the condi-
tions used, this antibody is capable of distinguishing between 
GABARAPL1 and GABARAP. Incubation of the PTG-NTER 
antibody with recombinant GABARAP produced the exact 
opposite effect, with a complete attenuation of the visible signal 
on the corresponding tissue section (Fig. 3F). This was surpris-
ing since this antibody showed some specificity in protein gel blot 
experiments (Fig. 2). Finally, recombinant GABARAP, when 
incubated with the antibody produced by immunization with 
the central peptide (CHEM-CENT), reduced staining in the last 
experiment to about the same extent as incubation with recom-
binant GABARAPL1 (Fig. 3I). The two antibodies produced 
against peptide sequences within the GABARAPL1 protein were 
Figure 2. protein gel blot analysis of anti-GABArApL1 antibodies specificity. pro-
tein gel blot analysis of HeK293 and HeK293:fLAG-GABArApL1-6His cells (A) and 
HeK293 cells transiently transfected with a Gfp-GABArAp or a Gfp-GABArApL1 
vector (B). Whole cell lysates (20–40 μg) were loaded on a 12% or 15% sDs-pAGe 
and protein gel blotting experiments were performed using three different 
anti-GABArApL1 antibodies directed against the N-terminus (ptG-Nter), the 
full-length protein (ptG-fL) or the center of the protein (cHeM-ceNt) and control 
antibodies (anti-Gfp, anti-fLAG M2 and anti-Actin). A representative experiment 
of three performed is shown.
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only the PTG-FL antibody showed a specific staining, which was 
inhibited by a pre-incubation with the GABARAPL1 protein 
and not the GABARAP protein. All together, our results dem-
onstrate that only the PTG-FL antibody seems to be specific of 
GABARAPL1 in vitro and in vivo.
In the past, our studies have utilized alternatives to endog-
enous protein detection such as mRNA expression or overexpres-
sion of a recombinant GABARAPL1, due to the lack of available 
antibodies. The identification of only one of the two homologs 
has been limited, making it difficult to associate the cellular roles 
being examined to one protein or the other. Although the conclu-
sions obtained regarding the fundamental function of these two 
molecules in the cells remain valid, there is some doubt about the 
real implication of each of these proteins separately in the roles 
identified.
To conclude, experimenters should be very careful when 
working with anti-GABARAP and GABARAPL1 antibodies for 
we chose, the antibody raised against a peptide sequence within 
the central part of the GABARAPL1 protein was the least effi-
cient at discerning between the two proteins but, surprisingly, 
this antibody displayed a higher affinity for these proteins. 
Finally, the antibodies, raised against the N-terminus and the 
full-length protein, appear to be able to distinguish between the 
two homolog proteins under the conditions used. It is worth not-
ing, however, that even these antibodies have, under other condi-
tions, recognized the recombinant GABARAP protein in protein 
gel blotting experiments16 and one must therefore be vigilant of 
the protocol used when using these antibodies for GABARAPL1 
detection. Our protein gel blot experiments indicated that the 
PTG antibodies seem to be specific of GABARAPL1 but when 
we analyzed their specificity in vivo, we observed some differ-
ences. Indeed, when we pre-incubated each antibody with either 
GABARAP or GABARAPL1 before performing an immunohis-
tochemistry staining on mouse brain sections, we observed that 
Figure 3. immunohistochemical analysis of blocking protein experiments. immunohistochemical analysis of rat brain tissue with anti-GABArApL1 anti-
bodies. one μl of pure anti-GABArApL1 antibody was pre-incubated in either pBst alone, 0.5 nmol fLAG-GABArAp-6His in pBst or 0.5 nmol fLAG-GAB-
ArApL1-6His in pBst for 2 h before incubation on rat brain sections overnight as described in the material and methods. scale bar represents 20 μm.
© 2011 Landes Bioscience.
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followed by a second centrifugation at 20,000 g for 30 min at 4°C 
to clear the lysates. The FLAG-GABARAP-6HIS and FLAG-
GABARAPL1-6HIS recombinant proteins were then purified 
using a Ni-NTA Agarose column Purification System (Qiagen 
30210) according to the manufacturer’s protocol. Briefly, protein 
lysates were incubated with 500 μl of packed Ni-NTA resin per 
500 ml bacterial culture for 2 h at 4°C. The resin was then cen-
trifuged at 5,000 g for 5 min at 4°C and washed three times with 
at least two volume equivalents of Wash buffer [20 mM TRIS-
HCl, pH 7.2–7.3, 20% Glycerol, 0.2 mM EDTA pH 8.0, 100 
mM KCl, 20 mM Imidazole, 10 mM β-EtSH, 0.5 mM phenyl-
methylsulfonyl fluoride (PMSF)] followed by a centrifugation at 
10,000 g for 1 min at 4°C. The purified protein was eluted by 
incubation with two volume equivalents of Elution buffer (20 
mM TRIS-HCl, pH 7.2–7.3, 20% Glycerol, 0.2 mM EDTA 
pH 8.0, 100 mM KCl, 10 mM β-EtSH, 0.5 mM PMSF) con-
taining increasing concentrations of Imidazole (100–500 mM). 
Recombinant protein concentration was determined by compari-
son to a range of known BSA quantities on a 12.5% SDS-PAGE 
followed by Coomassie staining.
Cell culture. HEK293 (Human Embryonic Kidney) and 
HEK293:FLAG-GABARAPL1-6HIS cells were cultured in 
DMEM (Dulbecco’s Minimum Essential Medium, PAA, E15-
891) supplemented with 2 mM Stable L-Glutamine (PAA, 
M11-006), 100 μg/ml penicillin, 100 μg/ml streptomycin 
(Invitrogen, 15140) and 10% fetal bovine serum (FBS, PAA, 
A15-101) in a 5% CO
2
 incubator at 37°C. Transient transfection 
of the HEK293 cells plated in a 6-well plate was accomplished 
with 500 ng of either pGFP-GABARAP or pGFP-GABARAPL1 
and 1 μl of TransFast reagent (Promega, E2431) per well, follow-
ing the manufacturer’s instructions.
Tissue fixation and cryoprotection. Animals were anaesthe-
tized by an intraperitoneal (i.p.) injection of 7% chloral hydrate 
(ROTH, K318.3) and perfused as previously described in refer-
ence 21, with 0.9% NaCl followed by ice-cold 1% paraformal-
dehyde (PFA, ROTH, 0335.4) fixative in PBS (0.137 M NaCl, 









brains were subsequently post-fixed in 1% PFA for several hours 
at 4°C and cryoprotected by saturation in a 15% sucrose solution 
(Sigma, 17 994-9) at 4°C overnight. Tissues were frozen on dry 
ice in OCT (Tissue Tek 4583), sectioned into 10 μm sections at 
-20°C using a cryostat-microtome (Microm, HM560) and placed 
on gelatin-coated slides (ROTH, 4275.1) and stored at -40°C.
Immunohistochemistry. For immunohistochemical stain-
ing, slides were prepared by rehydrating in PBS-T (PBS with 
0.3% Triton X100) for three 5-min washes at room temperature. 
Tissue was subsequently incubated with the appropriate primary 
antibody dissolved in milk diluant (PBS-T containing 1% bovine 
serum albumine, 10% lactoproteins and 0.01% sodium azide) 
overnight at room temperature. Primary antibodies used include: 
anti-ATG8L (PTG-FL, rabbit polyclonal, Proteintech, 11010-1-
AP, 1:200), anti-GABARAPL1 (PTG-NTER, rabbit polyclonal, 
Proteintech, 18721-1-AP, 1:200), anti-GABARAPL1 (CHEM-
CENT, rabbit polyclonal, Chemicon Millipore, AB15278, 
1:200). Slides were then washed three times with PBS-T for 
5 min each at room temperature before being incubated with 
both in vitro and in vivo detection since they most likely cross-
react and detect both proteins simultaneously. It would be judi-
cious to either first demonstrate the degree of specificity of the 
antibody or intentionally target the two proteins together, as has 
previously been demonstrated for siRNA experiments.17 In the 
future, the production of specific monoclonal antibodies would 
be more than useful to further characterize the function of each 
protein independently in vivo, as they have been described as 
playing an important role in various cellular and physiological 
processes such as apoptosis, autophagy, brain receptor transport 
or tumor progression.
Materials and Methods
Animals. All animal care and experimental protocols adhere to 
the institutional guidelines. Cerebral tissue from an adult male 
Sprague Dawley rat was used for competing protein experiments.
Vectors. To construct the psBET-FLAG-GABARAP-6HIS 
and psBET-FLAG-GABARAPL1-6HIS vectors, gabarap and 
gabarapl1 cDNA were amplified by polymerase chain reaction 
(PCR) from the pcDNA3.1-gabarap and pcDNA3.1-gabarapl1,18 
plasmids using the following primers: 5'-AAA TCT AGA ATG 
AAG TTC GTG TAC AAA GA-3' and 5'-TTT GGA TCC CAG 
ACC GTA GAC ACT TTC GT-3' for gabarap and 5'-AAA TCT 
AGA ATG AAG TTC CAG TAC AAG GA-3' and 5'-TTT AGA 
TCT CTT CCC ATA GAC ACT CTC AT-3' for gabarapl1. The 
protocol used the following settings: 94°C for 2 min, followed 
by 35 cycles of 94°C for 30 sec, 54°C for 30 sec, and 72°C for 
1 min and one final extension at 72°C for 10 min. The reac-
tions were performed in a 25 μl volume containing 0.2 μM of 
each primer, 200 μM dNTPs, 1.5 mM MgCl
2
, 15 ng of template 
DNA and 1 U of Go Taq DNA Polymerase (Promega, M3171). 
The PCR fragments were then purified using the NucleoSpin 
Extract II Kit (Macherey-Nagel, 740609.10) and ligated into 
the pGEM-T easy vector (Promega, A1360) using a T4 DNA 
ligase (Promega, M1801) according to the manufacturer’s proto-
col. The gabarap and gabarapl1 cDNA were then digested with 
XbaI (Fermentas, FD0684) and BamHI (Fermentas, FD0054) 
or BglII (Fermentas, FD0083), respectively and subcloned into 
the psBET-Flag/6His vector19 to produce the psBET-FLAG-
GABARAP-6HIS and psBET-FLAG-GABARAPL1-6HIS vec-
tors, respectively. Plasmid sequences were confirmed by DNA 
sequencing using the previously described method in reference 
20 (3130 Genetic Analyzer, Applied Biosystems).
Recombinant protein expression and purification. 
BL21-DE3 E. coli transformed with psBET-FLAG-GABARAP-
6HIS or psBET-FLAG-GABARAPL1-6HIS were grown in 100 
ml Luria-Bertani (LB) broth in the presence of 100 μg/ml kana-
mycine at 37°C. Protein expression was induced with 0.5 mM 
Isopropyl-β-D-Thiogalactopyranoside (IPTG) for 2 h. Bacteria 
were then pelleted at 5,000 g for 10 min at 4°C and resuspended 
in 5 ml of Sonication buffer (20 mM TRIS-HCl, pH 7.2–7.3, 
20% Glycerol, 0.2 mM EDTA pH 8.0, 500 mM KCl, 10 mM 
Imidazole, 10 mM β-EtSH, 1 mg/ml lysozyme) per gram of bac-
teria. The bacterial solution was then incubated on ice for 30 
min and sonicated three times for 15 sec (Sonics and Materials) 
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or 15% polyacrylamide gel in running buffer (25 mM Tris base, 
200 mM glycine and 0.1% SDS) at 120 V, using a Biorad Power 
Pack 1000. Proteins were transferred onto Immun-Blot PVDF 
0.2 μm membranes (Biorad, 1620177) for 1 h at 4°C at 100 V in 
protein gel blot transfer buffer (25 mM Tris base, 200 mM gly-
cine and 10% methanol). Membranes were subsequently blocked 
in TBS-T (199 mM TRIS-HCl, pH 7.4, 1.36 mM NaCl, 0.1% 
Tween 20) with 5% skim milk powder. Membranes were blotted 
with antibodies diluted in TBS-T supplemented with 0.5% skim 
milk against ATG8L (PTG-FL, rabbit polyclonal, Proteintech, 
11010-1-AP, 1:2,000), GABARAPL1 (PTG-NTER, rabbit 
polyclonal, Proteintech, 18721-1-AP, 1:2,000), GABARAPL1 
(CHEM-CENT, rabbit polyclonal, Chemicon Millipore, 
AB15278, 1:2,000), GFP (rabbit polyclonal, Millipore, AB3080, 
1:5,000), FLAG M2 (mouse monoclonal, Sigma, F1804, 
1:1,000) and Actin (rabbit polyclonal, Sigma, A5060, 1:3,000). 
The secondary antibody horseradish peroxydase-coupled anti-
rabbit IgG was prepared in TBS-T containing 0.5% skim milk 
powder. Binding of antibodies to membranes was detected by 
Enhanced Chemiluminescence Plus Reagent (ECL Plus, GE 
Healthcare Life Sciences, RPN2132), according to the manufac-
turer’s protocol.
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the appropriate secondary antibody diluted in milk solution 
for 1 h at room temperature. The secondary antibody used 
was the Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, 
A11034, 1:800). Finally, the slides were washed with PBS-T 
three times for 5 min and coverslips were mounted with 70:30 
glycerol:PBS-T.
Competing protein experiments. For immunohistochemi-
cal protein competing experiments, antibodies were incubated 
with either 0.05 or 0.5 nmol of purified recombinant protein 
(FLAG-GABARAP-6HIS or FLAG-GABARAPL1-6HIS) per 
1 μl of pure antibody (either anti-ATG8L from Proteintech at 
0.247 μg/μl, anti-GABARAPL1 from Proteintech at 0.773 μg/
μl, or anti-GABARAPL1 from Chemicon at 0.62 μg/μl) diluted 
in PBS-T experiments for 2 h prior to detection experiments as 
described above.
Confocal microscopy. Tissue sections were examined with 
a fluorescence laser scanning confocal microscope Fluoview 
FV1000 BX (Olympus, France) and images were captured with 
a 40x/0.75 NA objective and a DP 75 numeric camera using the 
Fluoview FV1000 software (Olympus, France). All figures were 
assembled using Adobe Illustrator CS software.
Protein gel blot analysis. Cells were lysed using the follow-
ing lysis buffer: [50 mM Tris pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1% Triton X100, protease inhibitor cocktail (Sigma, 
P8340)] then 20–40 μg of cell lysates were resolved on a 12% 
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